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Abstract 34 
 35 
By their interaction with IgG immune complexes FcγR and complement link innate and adaptive 36 
immunity showing functional redundancy. In complement-deficient mice not only IgG 37 
downstream effector functions are often impaired but also adaptive immunity. Based on a 38 
variety of model systems utilising FcγR KO mice, it has been concluded that FcγR are also key 39 
regulators of both innate and adaptive immunity. However, several of the model-systems under-40 
pinning these conclusions suffer from flawed experimental design. To address this issue in the 41 
absence of these caveats we generated a novel mouse model deficient for all FcγR 42 
(FcγRI/II/III/IV-/- mice). 43 
These mice displayed normal development and lymphoid and myeloid ontogeny. Although IgG-44 
effector pathways were impaired, adaptive immune responses to a variety of challenges, 45 
including bacterial infection and IgG-immune complexes, were not. Like FcγRIIb-deficient 46 
mice, FcγRI/II/III/IV-/- mice developed higher Ab titres, but no autoantibodies. These 47 
observations indicate a redundant role for activating FcγRs in the modulation of the adaptive 48 
immune response in vivo. We conclude that FcγR are downstream IgG-effector molecules with 49 
a restricted role in the ontogeny and maintenance of the immune system as well as regulation of 50 
adaptive immunity. 51 
 52 
 53 
 54 
  55 
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INTRODUCTION 56 
Adequately defining the in vivo role of the receptors for IgG, FcγR, is severely hampered not 57 
only by the complexity of the FcγR gene family itself but also because of their functional 58 
redundancy with the complement system. FcγR and complement link innate and adaptive 59 
immunity on two levels. First of all, they mediate the activation of downstream effector 60 
pathways of innate immune cells by antigen (Ag) specific IgG. Secondly, they are involved in 61 
the IgG immune complex (IC) mediated regulation of adaptive immunity. 62 
Four different FcγR, have been identified in the mouse. The IgG binding α-chains of the 63 
activating FcγRI, FcγRIII and FcγRIV, are associated with the FcR γ chain, a signal 64 
transduction subunit which is also required for cell surface expression (1). The activating FcγR 65 
are counterbalanced by the inhibiting receptor FcγRIIb. The four FcγR, are expressed in 66 
different combinations on a variety of immune cells, mainly myeloid effector cells.  67 
The in vivo role of FcγR has been extensively studied by analyzing the phenotype of mice 68 
deficient either for one or combinations of two or three FcγR or the FcR γ chain. By establishing 69 
a variety of disease models such as arthritis, hemolytic anemia, anaphylaxis and lupus like 70 
disease in these KO mice, we and others have shown that FcγR play an important role in the 71 
downstream antibody (Ab) effector pathways which drive the pathogenesis in these diseases (2). 72 
However, by using antibodies with a mutation in their Fc domain, destroying FcγR binding 73 
without affecting interactions with complement, it has recently been shown that several IgG 74 
downstream effector functions can be mediated also by complement (3).  75 
Mice deficient in the early pathway components C1q, C3 and C4 and the complement receptors 76 
Cr1/Cr2 have impaired humoral responses to T cell dependent and T cell independent Ag (4-6) 77 
indicating that the complement system plays an important role in priming and regulation of the 78 
adaptive immune response (7). Moreover, C1q deficient mice develop spontaneously lupus like 79 
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disease. A series of observations suggest that FcγR also play a role in priming and 80 
regulation of adaptive immunity and the maintenance of immune tolerance. Ag-specific IgG1, 81 
IgG2a, and IgG2b enhance Ab and CD4+ T cell responses to soluble protein Ag via activating 82 
FcγRs, probably by increasing Ag presentation by dendritic cells to Th cells (8). With Ag-83 
specific IgG3, an IgG subclass not interacting with FcγR, this process is complement dependent 84 
(9). In FcR γ chain KO mice, immunized with the model Ag KLH, the delayed-type 85 
hypersensitivity (DTH) response after challenge is significantly decreased compared to the DTH 86 
in WT mice. Moreover, the secondary responses of CD4+ T cells to Ag and Ab formation were 87 
also reduced in these mice (10). These data suggest that activating FcγRs on antigen presenting 88 
cells (APCs) facilitate Ag presentation resulting in efficient priming of Th cell responses in vivo 89 
in an IC-dependent manner which is required for a full-blown Ab response. We and others have 90 
shown that soluble IgG-IC enhance cross presentation by DCs resulting in a strong induction of 91 
the proliferation of antigen specific CTLs (11-14). It is generally believed that FcγR play an 92 
important role in this process (15).  93 
Combined, these observations suggest an important role of activating FcRs in modulating the 94 
adaptive immune response. In addition, cross-linking the B cell receptor with FcγRIIb by IgG-95 
IC results in down regulations of Ab production. FcγRIIb deficient mice develop higher Ab 96 
titers compared to WT mice (16). Moreover it has been shown that FcγRIIb deficient mice when 97 
backcrossed into C57BL/6 background develop spontaneously lupus like disease (17).  98 
In conclusion, many in vivo observations in WT and FcγR KO mice suggest a pleiotropic role of 99 
FcγR in the immune system. However, many of these studies have some flaws. Several studies 100 
were performed in FcR γ chain deficient mice. The FcR γ chain is a promiscuous signal 101 
transduction subunit, associated with at least nine other receptor complexes (18). Most FcγR 102 
KO mice have been generated by gene targeting in 129-derived ES cells, and subsequently 103 
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backcrossed into C57BL/6 background. We have shown that after backcrossing the remaining 104 
129-derived sequences flanking the FcγRIIb KO allele, including the hypomorphic autoimmune 105 
susceptibility SLAM locus (19) cause the autoimmune phenotype of the FcγRIIb KO mouse on 106 
mixed 129/C57BL/6 background whereas the FcγRIIb deficiency only enhances the lupus like 107 
disease (20). In many in vivo cross-presentation studies bone marrow derived DCs ex vivo 108 
loaded with IgG-IC of the model antigen chicken Ovalbumine (OVA) induced strong 109 
proliferation of adoptively transferred OVA antigen specific T cells (11,12,14). However, the 110 
endogenous anti-OVA cytotoxic T cell response was very low (21). Moreover, in vivo cross 111 
presentation of IgG-IC derived Ag was impaired in C1q deficient mice (22).    112 
To address these issues in the absence of these caveats we generated a novel C57BL/6 mouse 113 
model deficient for all four FcγR but expressing the FcR γ chain and analyzed its phenotype. 114 
Although, as expected, we could confirm that a variety of IgG downstream effector pathways 115 
were impaired, the overall characteristics of the immune system of these mice and WT control 116 
mice were very similar. Their B and T cell responses were not impaired. Like FcγRIIb-117 
deficient mice, FcγRI/II/III/IV-/- mice developed higher Ab titres, but no autoantibodies with 118 
age. We conclude that, in contrast to complement, FcγR have little or no role in the ontogeny 119 
and the maintenance of the immune system. Their role in priming and regulation of the 120 
adaptive immune response appears redundant. 121 
 122 
 123 
 124 
 125 
 126 
 127 
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Material and Methods 128 
 129 
Mice 130 
Mice were housed and all experiments were performed at the SPF animal facilities of the 131 
laboratory animal facility (PDC) of the Leiden University Medical Center (LUMC) or 132 
University of Cambridge (Salmonella infection). The health status of the animals was monitored 133 
over time. Animals tested negative for all agents listed in the FELASA  (Federation of European 134 
Laboratory Animal Science Associations) guidelines for SPF mouse colonies (23). 135 
All mouse studies were approved by the animal ethics committee of the LUMC. Experiments 136 
were performed in accordance with the Dutch Act on Animal Experimentation and EU 137 
Directive 2010/63/EU ('On the protection of animals used for scientific purposes'). C57BL/6J 138 
mice were purchased from Charles River the Netherlands. All FcγR KO mice were generated in 139 
the transgenic mouse facility of the LUMC (Figures 1 and S1). The EIIaCre deleter strain 140 
(n=20 on C57BL/6J background), was a kind gift of Dr. Heiner Westphal. The Flp deleter strain 141 
C57BL/6-Tg(CAG-flpe)36Ito/ItoRbrc, was purchased from Jackson Laboratories Bar Harbor, 142 
Me. Mice were routinely checked for their genotype by PCR. 143 
 144 
Cells and cell lines 145 
B3Z is an ovalbumin (OVA) 257-264 (SIINFEKL) –specific H-2Kb restricted co-stimulatory 146 
independent T cell hybridoma cell line. Intraperitoneal thioglycolate elicited macrophages of 147 
WT C57BL/6 and FcγRI/II/III/IV-/- mice were isolated by abdominal lavage with 5 ml PBS 48h 148 
after intraperitoneal injection of 1.5 ml 4% thioglycollate medium (Becton Dickinson, Mountain 149 
View CA). 150 
 151 
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Collagen Ab Induced Arthritis (CAIA)  152 
Mice were injected intravenously (i.v.) with 4 mg of a cocktail of four different mouse anti- 153 
mouse collagen type II IgG monoclonal Abs (Equimolar mix of M2139 (IgG2b) + CIIC1 154 
(IgG2a) + CIIC2 (IgG2b) + UL1 (IgG2b) on day 0 and in addition on day 3 with 100μg of LPS 155 
from E.coli 055:B5 (Sigma-Aldrich L2880) in 100μl of PBS intraperitoneally. At day 10 an 156 
additional amount of 4 mg of a cocktail of four different mouse anti-mouse collagen type II IgG 157 
monoclonal Abs was injected IP to boost the response. From day 7 onwards development of 158 
arthritis was monitored daily in a blind manner using a caliper to measure footpad swelling (24). 159 
 160 
Anaphylaxis  161 
Mice were sensitized by injecting iv 400 μg of pyrogen-free mouse anti-TNP IgG2a in saline 162 
and challenged 4 hrs. later by i.v. injection of 1 mg pyrogene-free DNP-HSA (2,4-163 
dinitrophenylated human serum albumin) (A6661 Sigma-Aldrich) in saline per mouse (25). For 164 
the monitoring of blood pressure, the mice were anesthetized by i.p. injection of ketamine 165 
(75mg/kg), dexdomitor (0.2mg/kg) and atropine (0.5mg/kg) in saline. After induction of 166 
anesthesia, the femoral artery and femoral vein were catheterized. The artery catheter was 167 
connected to the blood pressure monitor and blood pressure was allowed to stabilize for ≥5 min. 168 
Subsequently, the mice were injected i.v. via the femoral vein catheter with DNP-HSA. Blood 169 
pressure was monitored for ≥30 min after OVA injection, using a physiological pressure 170 
transducer (AD Instruments, Colorado Springs, CO). The signal was acquired and digitized in 171 
PowerLab (AD Instruments), sampled at 200 Hz, and analyzed offline using LabChart (AD 172 
Instruments). 173 
 174 
 175 
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Ab dependent Cellular phagocytosis (ADCP) 176 
WT C57Bl/6 and FcγRI/II/III/IV-/- mice were injected with 25 µg of the rat IgG2b 2.43 Ab (in-177 
house production) intraperitoneally to deplete CD8+ T cells. One day before, and three days 178 
after the depleting Ab injection CD8+ T cell numbers were analyzed in blood using 179 
flowcytometry and quantified as a percentage of total CD3+ cells. As determined with Surface 180 
Plasmon Resonance, the rat IgG2b antibody has a binding preference for activating mouse FcγR 181 
(activating-to-inhibitory FcγR binding [A/I] = 40) (26).     182 
 183 
In vitro uptake and cross presentation of immune complex derived Ag 184 
In vitro uptake and cross-presentation of OVA-IC derived Ag by DCs were studied by pre-185 
forming complexes of OVA and rabbit polyclonal anti-OVA ab (Cappel) in a ratio of 1 to 30, 186 
and incubating 5 µg of these complexes with 25.000 BM-DC cells in normal DC conditioned 187 
medium, as described (27). Rabbit IgG binds to all mouse FcγR (27,28). For uptake, Alexa488-188 
labeled OVA was used, and measured using flow cytometry, with or without quenching of 189 
extracellularly bound fluorescent OVA by addition of trypan blue (Sigma-Aldrich). For Cross 190 
presentation, 25.000 BMDC were incubated with 50.000 B3Z cells. B3Z cells recognize the 191 
minimal SIINFEKL OVA-CTL epitope in MHC class I. Recognition leads to up-regulation of 192 
the transcription factor NFAT which activates a LacZ-reporter gene by binding to its IL-2 193 
promoter (29).  After overnight incubation with BM-DC the B3Z cells were incubated with a 194 
lysis buffer containing the CPRG substrate for β-gal (PBS +1% 9 mg/mL CPRG + 0.9% 1m 195 
MgCl2 + 0.125% NP40 + 0.71% 14.3m β-mercaptoethanol) at 37 °C until the color reaction had 196 
progressed sufficiently for readout in a plate reader measuring the optical density at 590 nm. A 197 
peptide with the minimal OVA epitope SIINFEKL (100 ng/mL in PBS) that directly binds to 198 
MHC class I was used as a positive control and unstimulated D1 cells (a dendritic cell line, as 199 
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described (27) as negative controls. 200 
 201 
In vivo cross-presentation of immune complex derived Ag 202 
CD8+ T cells were isolated from spleen and lymph nodes from OT-I/CD45.1 mice with the BD 203 
CD8+ lymphocyte enrichment kit and labeled with CFSE. Three million OT-1 T cells were i.v. 204 
injected in recipient mice. One day later either 200 µg rabbit polyclonal anti-OVA Ab (Cappel) 205 
or non-specific rabbit sera (negative control) was injected i.v. followed 30 minutes later by 5 µg 206 
OVA (Worthington Biochemicals) or in house synthesized peptide with the minimal SIINFEKL 207 
OVA epitope (positive control). Three days later mice were sacrificed, spleens were isolated and 208 
proliferation of CFSE-labelled OT-1 T lymphocytes was analysed in single cell suspensions by 209 
flow cytometry gated on CD8+ and CD45.1+ cells.  210 
 211 
Quantitation of Immune complex clearance 212 
Age- and weight-matched naive mice received an i.v. injection of 100 μg rabbit 213 
IgG anti-ovalbumin (Cappel) followed by an i.v. injection of 5 μg Alexa Fluor 488/647 labeled 214 
ovalbumin (Life Technologies) 15 minutes later. At indicated time points blood was drawn and 215 
serum was collected. 5 μl serum was mixed with sample buffer, heated at 95o C for 5 minutes 216 
and loaded on SDS/PAGE. Fluorescent ovalbumin was quantified directly from the SDS/PAGE 217 
gels by a Typhoon 9410 Variable mode imager (GE Healthcare Bio-Sciences) and ImageQuant 218 
TL v8.1 software (GE Healthcare Life Sciences).  219 
At different time-points after injection, mice were sacrificed and a single lobe of liver was 220 
isolated and imaged by IVIS Spectrum (PerkinElmer) using excitation at 605 nm and measuring 221 
emission at 680 nm with an exposure time of 2 seconds.  222 
 223 
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Flow cytometry 224 
Single cell suspensions were made from spleen, thymus, lymph nodes, bone marrow and from 225 
lavage of peritoneal cavity 24hr after injection of 1.5ml thioglycolate. For analysis of myeloid 226 
cells from spleen, organs were incubated for 30 minutes with Liberase (Sigma-Aldrich) 227 
according to manufacturer’s protocol. Cells were blocked with 10% normal mouse serum. 7-228 
AAD (Life Technologies) was used to exclude dead cells.  229 
Abs for the following surface markers were used in this study: CD11c (clone HL3), CD8b 230 
(clone 53-5.8), CD19 (clone 1D3), CD90.1 (clone H1S51), and FcγRI clone X54-5/7.1 ( all 231 
from Becton Dickinson). CD3ε (145-2c11), B220 (RA3-6B2), and CD45.2 (clone 104) (all from 232 
eBioscience). CD4 (clone RM4-4), F4-80 (clone BM8), Ly6C (HK1.4), and Ly6G (clone 1A8) 233 
(all from Biolegend), FcgRIIb (clone Ly17.2 produced in house); FcγRIII (clone 275003, from 234 
R&D) and FcγRIV (clone 012, from Sino Biological).  235 
 236 
Serum levels of IgG subclasses  237 
Serum was collected from 10 months old naive FcγRI/II/III/IV-/- and WT C57Bl/6 mice.  238 
Elisa was performed with goat anti mouse IgG (Becton Dickinson), and goat anti mouse IgG, 239 
IgG1, IgG2a or IgG2b HRP (Southern Biotech) and TMB substrate (Dako). Reaction was 240 
stopped with 1M H2SO4 and absorption was measured at 450 nm. 241 
For antigen-specific antibody titres in serum; Mice were immunized with 50 μg TNP-BSA in 242 
100 μl CFA (1:1 emulsion with PBS) injected s.c. at day 0 and boosted at day 14 and 28 with 243 
25 μg TNP-BSA in 100 μl IFA (1:1 emulsion with PBS). Ab titres in sera collected at day 36 244 
were assessed with ELISA. Streptavidin-coated 96-wells plates were incubated with 1nmol/ml 245 
biotin-BSA and blocked with 5% non-fat milk. Secondary Ab was goat-anti-mouse horseradish 246 
peroxidase (HRP). Substrate ABTS (Code no. S1599, Dako) was added, and absorption was 247 
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measured at 415nmSerum levels of IgG class autoantibodies were determined using ELISA 248 
plates coated with 5μg/ml of dsDNA (Sigma-Aldrich) or 5μg/ml of histone (Sigma-Aldrich) or 249 
4μg/ml of chromatin, respectively, as previously described (30). Serum levels of binding 250 
activities against dsDNA, histone, and chromatin were expressed in units by reference to a 251 
standard curve obtained by serial dilution of a standard serum pool from (NZB × NZW)F1 mice 252 
ages >8 months, containing 1,000 unit activities/ml. Serum levels of IgG Abs were measured 253 
using HRP conjugated anti-mouse IgG secondary Abs (Southern Biotech, Birmingham AL, 254 
USA) and detected at OD450 nm by using TMB Substrate Reagent(BD). 255 
 256 
Infection with Salmonella live vaccine 257 
Mice were infected with the Salmonella Typhimurium (STm) SL3261, and attenuated aroA 258 
strain (31). Live bacteria for parenteral immunization were prepared from a 16 hr. static culture 259 
of STm SL3261 in LB Broth, diluted 1/100 in PBS and administered by i.v. injection into the 260 
tail vein (~106 CFU/mouse). Actual inoculum dose was determined by plating dilutions on LB 261 
Agar. 262 
Salmonella induces Th1 T-cell responses. IFNγ and IL2 production correlate well with T-h1 263 
responses to Salmonella. T-cell stimulation assays and cytokine measurement after infection 264 
with Salmonella live vaccine were performed as follows: CD4+
 
T cells were positively enriched 265 
from spleens using magnetic bead-conjugated Abs (Miltenyi Biotec), according to 266 
manufacturer’s instructions. Purity was assessed by flow cytometry on a FACSCalibur machine 267 
(Becton Dickinson). CD4+ T cells were stimulated with Salmonella Ag or anti-CD3e (clone 268 
145-2C11, eBioscience) and anti-CD28 (clone 37.51, eBioscience) as positive control in the 269 
presence of mitomycin C-treated (25 mg/ml; 37°C for 30 min) splenic Ag presenting cells. 270 
Salmonella Ag was alkali-treated Salmonella Typhimurium SL1344. Levels of IFN-γ and IL-2 271 
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produced at 72 hr and 24 hr were determined using Duoset ELISA kits (R & D Systems) 272 
according to manufacturer’s instructions. 273 
Anti-LPS Abs after infection with Salmonella live vaccine were detected by ELISA as follows: 274 
Salmonella Typhimurium LPS (Sigma-Aldrich) was dissolved in water containing sodium 275 
deoxycholate (0.5% w/v). Microtitre plates (Greiner Bio-One) were coated overnight at 37°C 276 
with LPS at 5 μg/ml in carbonate buffer. Serum sample serial dilutions in PBS-Tween+1% BSA 277 
were applied in duplicate and incubated. Plates were washed and total Ab detected with HRP-278 
conjugated goat anti-mouse Ab (Southern Biotech), detection was with SigmaFast OPD 279 
substrate (Sigma-Aldrich) with absorbance read FLUOstar Omega (BMG Labtech). 280 
 281 
Complement analysis 282 
Plasma samples were collected from CO2 euthanized mice via heart puncture and put directly 283 
on ice. EDTA-plasma was collected with syringes pre-treated with EDTA and tubes with final 284 
EDTA concentration of 10mM. Blood was kept on ice for 30-120 min, centrifuged twice 285 
at 3000-5000g for 10 minutes at 4°C. Samples were pooled and aliquoted to single use batches 286 
and stored at -80°C. 287 
Measurement of functional pathway activities was performed in plasma of mice as described 288 
(32) In brief, complement activation was induced by incubation of serial dilutions in ELISA 289 
plates (Nunc Maxisorp plates, Thermo Fisher Scientific) coated with human IgM, mannan and 290 
LPS to induce Classical Pathway, Lectin Pathway and Alternative Pathway respectively. 291 
Activation of complement was either quantified at the level of C3 deposition, using an Ab 292 
directed against mouse C3b/C3c/iC3b, or at the level of C9 deposition using a rabbit anti-mouse 293 
C9 polyclonal Ab. Complement activity in the experimental samples was calculated using CD1 294 
serum as a standard which was put at 100 AU/ml. 295 
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Complement factors in plasma were quantified using specific sandwich ELISAs. C3 was 296 
quantified in the form of C3b/C3c/iC3b as previously described. C1q was quantified using 297 
rabbit anti-mouse C1q pAb (33). Mouse properdin was measured using coating with an anti- 298 
mouse properdin mAb, and detection with Rabbit anti-mouse properdin pAb-DIG, whereas C6 299 
and C9 were quantified using rabbit polyclonal anti-mouse C6 and rabbit polyclonal anti-mouse 300 
C9 (34,34). 301 
 302 
Histology 303 
Complete necropsy was performed following standard procedures. Tissues were fixed in 4% 304 
neutral buffered formalin, embedded in paraffin, sectioned at 5 μm and stained with 305 
haematoxylin and eosin and evaluated by light microscopy. Histopathological analysis was 306 
performed by a European board certified veterinary pathologist. All main organs were analysed. 307 
Light microscopy pictures were taken with a DP26 Olympus camera. 308 
 309 
Metabolic parameters 310 
In 12 weeks-old mice, body weight was measured and lean and fat mass was assessed by MRI-311 
based body composition analysis (Echo MRI, Echo Medical Systems, Houston, TX, USA). 312 
Blood was drawn from overnight fasted mice via tail vein into paraoxon (Sigma-Aldrich, St. 313 
Louis, MO) coated capillary tubes. After centrifugation, plasma was collected and triglyceride 314 
(TG), total cholesterol (TC), free fatty acid (FA), glucose and insulin levels were determined 315 
using commercially available kits (11488872 and 236691, Roche Molecular Biochemicals, 316 
Indianapolis; NEFA-C Wako Chemicals GmbH, Neuss, Germany; ab83390, Abcam, 317 
Cambrigde, UK; Instruchemie, Delfzijl, The Netherlands and Crystal Chem Inc., IL, USA, 318 
respectively). Indirect calorimetry measurements were performed using metabolic cages 319 
15 
 
(LabMaster System, TSE Systems, Bad Homburg, Germany) as previously described (35). 320 
 321 
FcγR expression during embryonic development  322 
Total RNA was extracted using QIAzol (5346994; Qiagen). 1 µg of total RNA was used for 323 
reverse transcription with the RevertAid H Minus First Strand cDNA Synthesis Kit (K1632; 324 
Thermo). qRT-PCR was performed in triplicate on a C1000TM Thermal cycler (Bio-Rad) with 325 
SYBR Green (170-8887; Bio-Rad). Data was normalized to β-actin. The following primers were 326 
used:  327 
β-Actin_F: GGCTGTATTCCCCTCCATCG; β-Actin_R: CCAGTTGGTAACAATGCCATGT;  328 
FcγRI_F: AAGTGCTTGGTCCCCAGTC; FcγRI_R: CTGCAGCCTGTGTATTTTCA;  329 
FcγRIIb_F: AATTGTGGCTGCTGTCACTG; FcγRIIb_R: GTTTCCTGGGAGAGCTGGA;  330 
FcγRIII_F: TGGGGACTACTACTGCAAAGG; 331 
FcγRIII_R:AGAAATAAAGGCCCGTGTCC      332 
FcγRIV_F: TGGAATGTACAGGTGCCAGA; FcγRIV_R: 333 
TTCCGTACAGGTCTGTTTTGC        334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
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RESULTS 344 
 345 
Generation of the FcγRI/II/III/IV quadruple KO mouse model 346 
To overcome the drawbacks of the existing FcγR KO mouse models we generated a novel 347 
mouse model in C57BL/6 background deficient for all four FcγR ligand binding chains while 348 
maintaining the promiscuous FcR γ signal transduction subunit. To this end we crossed a newly 349 
generated mouse model with a 90.4 Kb deletion on chromosome 1 deficient for the 350 
FcγRII/III/IV gene cluster (Fig.1) with our previously generated mouse model with a deletion of 351 
the FcγRI gene (25) located on chromosome 3 (Fig.1 and Fig.S1). The FcγRI/II/III/IV quadruple 352 
KO (FcγRI/II/III/IV-/-) offspring developed normally and showed normal breeding 353 
characteristics. The phenotype of the FcγRI/II/III/IV-/- mouse was analyzed in a series of in vitro 354 
and in vivo assays  355 
 356 
IgG downstream effector functions are impaired in FcγRI/II/III/IV-/- mice 357 
In order to confirm that the novel FcγRI/II/III/IV-/- mouse model had impaired known FcγR 358 
dependent IgG downstream effector functions, we studied IgG collagen Ab induced arthritis 359 
(CAIA), IgG induced passive systemic anaphylaxis and IgG induced antibody dependent cell 360 
mediated phagocytosis (ADCP) in these mice. As expected, FcγRI/II/III/IV-/- mice were almost 361 
completely resistant to CAIA initiated by intravenous (i.v.) injection of a cocktail of four 362 
different anti-collagen IgG Abs (Fig.2.a). CAIA cannot be induced easily in WT C57BL/6 mice, 363 
whereas FcγRIIb-/- mice are more sensitive (36). We therefore compared FcγRI/II/III/IV-/- mice, 364 
which lack FcγRIIb, with FcγRIIb-/- mice. In contrast to FcγRIIb-/- mice, FcγRI/II/III/IV-/- mice 365 
showed little footpad swelling. This confirms our previous results with K/BXN serum induced 366 
arthritis (37).  367 
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FcγRI/II/III/IV-/- mice were also resistant to passive systemic anaphylaxis, induced by 368 
challenging mice, sensitized by i.v. injection of IgG2a anti-TNP, with DNP-HSA, whereas WT 369 
C57BL/6 mice were not (Fig 2.b). The in vivo phagocytosis of CD8+ T cells by ADCP after 370 
intraperitoneal (i.p.) injection of rat IgG2b anti-CD8 Ab was completely abrogated in 371 
FcγRI/II/III/IV-/- mice (Fig.2.c) Together these results confirm that in our FcγRI/II/III/IV-/- 372 
mouse model IgG downstream effector functions are strongly impaired in a variety of in vivo 373 
experimental IgG induced inflammation models.   374 
 375 
In vivo Cross-presentation of soluble IgG-IC derived Ag is normal in FcγRI/II/III/IV-/- 376 
mice  377 
It has been demonstrated with a variety of in vitro and in vivo experiments that FcγR on Ag 378 
presenting cells facilitate the presentation of soluble IC-derived Ag to cytotoxic T cells, the 379 
process of cross presentation (12,14,15). In accordance with these observations the uptake of 380 
fluorescent labeled OVA-IgG IC by dendritic cells from FcγRI/II/III/IV-/- mice was strongly 381 
impaired in vitro compared to the uptake by dendritic cells from WT C57BL/6 mice (Fig.3.a). 382 
Moreover, as shown in Fig.3.b, the in vitro presentation of SIINFEKL peptide processed from 383 
OVA-ICs to B3Z hybridoma cells by FcγRI/II/III/IV-/- BMDCs was strongly inhibited. 384 
SIINFEKL synthetic peptide was used as control, and was presented by BMDCs from 385 
FcγRI/II/III/IV-/- and WT C57BL/6 control mice with similar efficiency indicating that MHC 386 
Class I expression was comparable between genotypes. These data show that FcγR are required for 387 
the in vitro IC uptake and subsequent MHC class I-restricted presentation of IC-derived 388 
peptides. 389 
Surprisingly, proliferation of adoptively transferred OT-1 CD8+ T cells was indistinguishable 390 
between FcγRI/II/III/IV-/- and WT C57BL/6 control mice. No difference in CFSE division was 391 
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observed after activation by IC, which were formed in situ by i.v. administration of OVA and 392 
subsequently anti-OVA Abs (Fig.3.c and d). Compared to WT C57BL/6 mice FcγRI/II/III/IV-/- 393 
mice showed a delay in clearance of IgG-IC from circulation (Fig.3.e and f) while the uptake of 394 
IgG-IC by the liver appeared to be decreased (Fig.3.g). These observations imply that in vivo, 395 
FcγR are dispensable for cross presentation of IgG-IC-derived Ag, but involved in clearance of 396 
IgG-IC from circulation.  397 
 398 
Adaptive immunity is not impaired in FcγRI/II/III/IV-/- mice 399 
In order to further characterize the adaptive immune system in the FcγRI/II/III/IV-/- mice the B 400 
and T lymphocyte compartments were analyzed by flowcytometry using a panel of fluorescent 401 
labeled Abs specific for B and T lymphocyte surface markers. No differences in percentages of 402 
CD8+
 
and CD4+
 
T cells in the thymus, lymph nodes or spleen were found between WT 403 
C57BL/6 and FcγRI/II/III/IV-/- mice (fig.4.a). Also, CD19+ B220+ B cell numbers in the spleen 404 
and bone marrow were comparable between WT C57BL/6 and FcγRI/II/III/IV-/- mice.  405 
After vaccination with BSA-TNP in CFA no gross differences were observed in BSA Ag 406 
specific Ab titers between WT C57BL/6 and FcγRI/II/III/IV-/- mice except a small increase in 407 
IgG1 in the FcγRI/II/III/IV-/- mice compared to WT C57BL/6 mice (Fig. 4.b), which can be 408 
explained by the absence of FcγRIIb on B cells in FcγRI/II/III/IV-/-
 
mice. These results are in 409 
agreement with the results of a previous experiment using a milder immunisation protocol (long 410 
synthetic peptide in saline with CpG) in our FcγRI/II/III/IV -/- mice (38) indicating that FcγRs 411 
are dispensible for T cell dependent B cell responses against a protein Ag. 412 
In order to test further the functionality of the adaptive immune response in FcγRI/II/III/IV-/- 413 
mice, the ability of these mice to respond to a bacterial infection was analyzed. We inoculated 414 
FcγRI/II/III/IV-/- and WT C57BL/6 mice with a live vaccine consisting of the non-virulent 415 
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SL3261 attenuated aroA Salmonella Typhimurium strain, and analyzed the T and B cell 416 
responses (Fig. 5. a and b). We did not observe significant differences in the induction of T cell 417 
responses between the groups. B cell responses were not hampered in FcγRI/II/III/IV-/- mice. 418 
The higher Salmonella-specific Ab responses detected in these mice are in keeping with the 419 
absence of FcγRIIb on their B cells (Fig.5.b). 420 
 421 
Normal Ab levels and no auto-Ab formation in aging FcγRI/II/III/IV-/- mice 422 
Serum titers of IgG in 10 months old naïve mice were comparable between FcγRI/II/III/IV-/- and 423 
WT C57BL/6 mice (Fig.6.a). FcγRIIb-/-
 
mice on mixed 129/C57BL/6 background develop high 424 
anti-nuclear Ab (ANA) titers with age (17) whereas FcγRIIb-/- mice on pure C57BL/6 425 
background hardly develop ANA (20). The FcγRII/III/IV deletion (on Chr1) has been generated 426 
in C57BL/6 derived ES cells whereas the FcγRI-/- mice were generated by gene targeting of the 427 
FcγRI gene (on Chr3) in 129 derived ES cells (25) and subsequent backcrossing into C57BL/6 428 
background (n>12). We compared ANA titres in the serum of old FcγRI/II/III/IV-/- mice with 429 
ANA titres in old FcγRIIb-/- mice on mixed 129/C57Bl/6 background (n≥ 8) and FcγRIIb-/-
 
mice 430 
on pure C57BL/6 background. Only FcγRIIb-/- mice generated by gene targeting in 129 derived 431 
ES cells and backcrossed into C57BL/6 background developed high ANA titres (Fig. 6.b, c and 432 
d) confirming that 129 derived FcγRIIb-flanking sequences (SLE16 on Chr1) (39) determine the 433 
development of ANA. The absence of FcγRIIb does not lower the threshold for the development 434 
of autoimmunity in FcγRI/II/III/IV-/-
 
mice. 435 
 436 
FcγR deficiency does not affect the development and homeostasis of the myeloid cell 437 
compartment 438 
Since the adaptive immune system was not impaired in FcγRI/II/III/IV-/- mice, we focused on 439 
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the innate immune system. Considering the extensive expression of FcγR on myeloid cells, we 440 
envisaged that FcγR mediated interactions might influence the development or differentiation of 441 
myeloid cells, and that the absence of these receptors in FcγRI/II/III/IV-/- mice could cause 442 
alterations in the innate immune compartment. We therefore evaluated the relative numbers of 443 
CD11c+/CD8a+ and CD11c+/CD8a- dendritic cells in bone-marrow and spleen (Fig.7.a) and the 444 
relative numbers of the different myeloid subsets in spleen, using a gating strategy described by 445 
Shawn Rose et al. (40) (Fig 7.b). We found no variances in percentages of either subset of cells 446 
between FcγRI/II/III/IV-/- and WT C57BL/6 mice. These results indicate that FcγR deficiency 447 
does not influence the development, differentiation or homeostasis of the cells on which they 448 
are normally most prominently expressed. 449 
 450 
No difference in complement, overall organ architecture and metabolic homeostasis 451 
between FcγRI/II/III/IV-/- and WT C57BL/6 control mice   452 
Since a direct connection between complement and FcγR effector pathway activation has been 453 
reported (41) we analyzed the complement system in FcγRI/II/III/IV-/- mice. We quantified the 454 
complement activity in an ELISA based system (32), upon initiation of the three pathways of 455 
complement activation. Both at the level of C3 and C9 deposition, there were no differences in 456 
complement activity between FcγRI/II/III/IV-/- and WT C57BL/6 mice (Fig. 8a). In line with 457 
this, also circulating levels of individual components, including C1q, properdin, activated C3 or 458 
C9 were not different between FcγRI/II/III/IV-/- mice and WT C57BL/6 control mice (Fig.8b). 459 
Circulating plasma levels of C6 were somewhat higher in FcγRI/II/III/IV-/- mice (Fig.8b), 460 
however this did not result in an increased terminal pathway complement activity (Fig.8a). 461 
Similarly, also complement activity measured at the level of C3 deposition was comparable 462 
between both groups. 463 
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Furthermore, we examined histological sections of several organs, including kidney, liver, lung, 464 
and spleen of 47 weeks old female mice. In keeping with the flow cytometry data, there were no 465 
abnormalities in overall architecture of these organs detectable in the FcγRI/II/III/IV-/- mice 466 
compared to WT C57BL/6 control mice (Fig.S2). There were no differences also regarding 467 
bronchus-associated lymphoid tissue (BALT) composition in representative lung sections 468 
between the 2 groups. Glomerular and kidney pathology was also absent. In representative liver 469 
sections from both groups lymphoid aggregates were absent. 470 
It has been postulated that the adaptive immune system, the intestine and microbiota govern a 471 
homeostatic metabolic function (42). B cells and pathogenic IgG promote insulin resistance in 472 
mice fed a high-fat diet (43). Moreover, we have recently shown that mice deficient for the FcR 473 
γ chain are protected against diet-induced obesity and insulin resistance (35), suggesting a role 474 
of activating FcR in intestinal and systemic metabolic homeostasis. Therefore, we measured a 475 
series of metabolic parameters in the FcγRI/II/III/IV-/- mice. Statistical analysis using unpaired 476 
t-tests did not reveal significant differences between measured parameters of FcγRI/II/III/IV-/- 477 
and WT C57BL/6 control mice. (Table S1).   478 
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DISCUSSION 479 
 480 
The novel mouse model presented here is the first C57BL/6 model exclusively and completely 481 
deficient for all four FcγR. This enabled us for the first time to study the consequences of 482 
complete FcγR deficiency without confounding factors. The phenotype of the FcγRI/II/III/IV-/- 483 
mouse demonstrates the dominant role of FcγR in IgG downstream effector pathways whereas 484 
complement is dispensable.  These results confirm older studies with single, double or triple 485 
FcγR KO mouse strains or FcR γ-/- mice, lacking all three activating receptors. However, the 486 
overall immune system of the FcγRI/II/III/IV-/- mice was surprisingly normal. Lymphoid 487 
organs, subsets of lymphoid and myeloid cells, complement and metabolic homeostasis were 488 
comparable to WT mice. 489 
Mammals are exposed to the Abs of their mother before birth. Also, before birth they have 490 
developed immune cells expressing a variety of FcγR (Fig.S3) which can directly interact with 491 
the Fc part of these Abs. The high affinity FcγRI binds monomeric IgG whereas the other FcγR 492 
are low affinity receptors which bind immune complexes. After birth the animals develop their 493 
own Abs in response to threats from the outside world. The lack of aberration in the phenotype 494 
of the FcγRI/II/III/IV-/- mouse suggests that the absence of all FcγR has little impact on the 495 
ontogeny and functionality of the immune system of these mice except their downstream Ab-496 
mediated inflammatory effector functions.  497 
Biological systems have a strong tendency to bypass a blockade in development and 498 
functionality by adaptation (44). The complement system and FcγR are redundant in the 499 
downstream effector pathways of IgG. However, the loss of FcγR was not compensated by 500 
increased activity of the complement system. We did not find indications for other 501 
compensation mechanisms in FcγRI/II/III/IV-/- mice. 502 
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Surprisingly, in vivo cross presentation of IgG-IC derived protein Ag, the adaptive immune 503 
response against Salmonella and the antibody response against a model antigen were almost 504 
indistinguishable between FcγRI/II/III/IV-/- and WT mice. This suggests strong redundancy in 505 
the involved adaptive immune pathways.   506 
The role of FcγR in cross presentation is still puzzling. We and others  (11-14) have shown 507 
that the cross presentation by DCs, in vitro loaded with IgG-IC, is FcR γ chain dependent. In 508 
contrast, more recently we demonstrated that the enhanced in vivo cross presentation of 509 
protein Ag derived from injected pre-formed IgG-IC is partially but not crucially dependent on 510 
the FcR γ chain (22) which is in line with previous data. Den Haan and Bevan showed that in 511 
the absence of FcR γ chain the uptake of i.v. injected IgG-IC and enhanced cross presentation 512 
by DC was not  impaired (45). An obvious explanation for this discrepancy is that an in vivo 513 
dominant FcR γ chain independent - most likely complement dependent - pathway is bypassed 514 
by loading DCs with IC in vitro. Our cross-presentation experiments with the FcγRI/II/III/IV-/- 515 
mice directly demonstrated that the IgG mediated enhanced cross presentation by DC in 516 
vitro loaded with IgG-IC is exclusively dependent on FcγR and not on other FcR γ chain 517 
associated receptor molecules. In contrast in vivo, FcγRs are not required, neither the 518 
inhibiting FcγRIIB nor the activating FcγRs. For the uptake of exogenous Ag DCs display 519 
besides FcγR a large variety of receptors such as c-type lectin receptors, TLR and complement 520 
receptors. We have found a pivotal role for C1q in the presentation of Ag derived from i.v. 521 
administered IgG-IC to CD8+ T cells in vivo (22) indicating that the complement system 522 
provides alternative pathways in IgG-dependent cross presentation.  523 
Remarkably, in comparison to WT control mice, FcγRI/II/III/IV-/- mice were not hampered in B 524 
cell responses but rather developed somewhat higher Ag-specific Ab titres upon immunization. 525 
This is not in agreement with the previous observation that FcR γ chain KO mice, lacking 526 
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functional expression of all three activating receptors, develop lower Ag specific Ab titers 527 
compared to WT mice (10). The discrepancy between these results might be explained by the 528 
use of different FcγR deficient mouse strains. The FcR γ chain is associated with at least nine 529 
other receptor complexes (18). Therefore, FcR γ chain deficiency might cause a more 530 
pleiotropic effect in immunity than FcγRI/II/III/IV deficiency. On the other hand, the 531 
FcγRI/II/III/IV-/- mouse lacks not only the activating FcγR but also the regulatory inhibiting 532 
FcγRIIb. The higher IgG titres in FcγRI/II/III/IV-/- mice suggest that the Ab response in these 533 
mice is affected by the deficiency of FcγRIIb on B cells, but not the deficiency of the three 534 
activating FcγR expressed on APCs. These data indicate that activating FcγRs on antigen 535 
presenting cells (APCs) are not required for the development of a full- blown antibody response 536 
by facilitating presentation of IC derived Ag resulting in efficient priming of Th cell responses 537 
as was suggested by previous results with FcR γ chain KO mice (10).  538 
Combined, our data suggest that in vivo the role of activating FcγR in the regulation of adaptive 539 
immunity by facilitating APC mediated presentation of IgG-IC derived Ag is dispensable.  The 540 
role of FcR has been implicated in enhancing an anti-tumor response by facilitating antigen-541 
presentation of IC derived tumor antigen after anti-tumor antibody therapy (46,47). In light of 542 
our findings, indicating that other FcγR-independent mechanisms play a dominant role, most 543 
likely complement associated, we propose to study IgG-IC mediated immune modulation in 544 
more detail in our FcγRI/II/III/IV-/- mice, as it is the first C57BL/6 model in which these 545 
questions can be answered without confounding factors. The use of antibodies with a mutation 546 
in their Fc domain, destroying FcγR binding without affecting interactions with complement, is 547 
limited to passive models (3), whereas our FcγRI/II/III/IV-/- mouse enables to study active 548 
models such as vaccination and infection.  549 
 550 
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Legends: 730 
 731 
Fig.1. Generation of the FcγRI/FcγRII/FcγRIII/FcγRIV quadruple KO (FcγRI/II/III/IV-/-) 732 
mouse strain.  733 
FcγRIIbfl/fl mice (13) were crossed with FcγRIIIfl/fl mice (supplemental figure S1). Offspring was 734 
selected for crossover between both floxed alleles. By crossing FcγRIIbfl/fl / FcγRIIfl/fl mice with 735 
the EIIaCre deleter strain a 90.4 kb fragment between the two most distant loxP sites, containing 736 
the main part of the FcγRIIb and FcγRIII gene and the complete FcγRIV gene, was removed 737 
resulting in a FcγRII/III/IV KO allele. The presence of the deletion was confirmed by PCR and 738 
DNA sequencing. The FcγRII/III/IV-/- mice were crossed with our previously generated FcγRI-/- 739 
mice (16) and FcγRI/II/III/IV-/- offspring was selected. The absence of all four FcγR was 740 
confirmed by FACS analysis.    741 
a. From top to bottom are depicted the genomic structure of the WT FcγRIIb/FcγRIV/FcγRIII 742 
gene cluster on chromosome 1, the gene targeting strategy for the generation of the floxed FcγRIIb 743 
and FcγRIII genes, the genomic structure after the crossover between the two floxed genes and 744 
subsequently after Cre mediated recombination. The locus is shown in reverse orientation in 745 
relation to the chromosomal nucleotide numbering. The exact location of the borders of the 746 
deletion (NC_000067.6:g 171054449_170964079del according to HGVS nomenclature) on 747 
chromosome 1 are depicted based on the mouse reference genome build GRCm38.p3 (C57BL/6J) 748 
provided by the Genome Reference Consortium.  749 
b. Core sequence flanking the remaining LoxP site within the 437 bp PCR fragment. 750 
c. Flow cytometry of thioglycolate elicited peritoneal cells from FcγRI/II/III/IV-/- (black lines) and 751 
WT C57BL/6 mice (grey lines) stained with fluorescent labeled antibodies specific for F4.80 and 752 
CD11b and antibodies specific for the different FcγR as indicated.  d. Agarose gel electrophoresis 753 
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of the unique PCR fragment bridging the 90.4 kb deletion. By using a FcγRIII specific ‘Geno Fw’:  754 
GAGGGCATCCGATTTCATTA and a FcγRIIb specific ‘Null B Rev’ 755 
GCTTCCATTGACCTGCCTAC primer, and genomic DNA from a FcγRII/III/IV-/-mouse as a 756 
template, a unique 437 bp fragment with the remaining LoxP site was synthesized. M: 100bp 757 
ladder, KO: FcγRII/III/IV-/- mouse; WT: WT control mouse. 758 
 759 
Fig.2. IgG downstream effector functions are impaired in FcγRI/II/III/IV-/- mice 760 
a. CAIA. From each phenotype footpad swelling was measured using a caliper. The average of 761 
combined left and right footpad swelling of the forepaws was plotted and expressed as Mean and 762 
SEM of increase in footpad thickness in mm. The area under the curve was calculated per mouse 763 
from day 7 until day 28 and a Mann-Witney test was performed for statistics. The response of the 764 
FcγRI/II/III/IV-/- mice was significantly lower compared to the response of FcγRIIb-/- mice 765 
(P=0.0159). Five mice per group.  One representative experiment out of two performed is shown. 766 
b. Passive systemic anaphylaxis. Time course of blood pressure, expressed in mm HG, as mean 767 
arterial pressure (MAP) plus SEM, in FcγRI/II/III/IV-/- and WT C57BL/6 mice passively 768 
sensitized by i.v. injection of mouse anti-TNP IgG2a, and challenged 4 hours later with DNP-769 
HSA. Six mice per group. Each time point is analyzed by a separate T test, and the curves are 770 
significantly different (p<0.01) from 5 minutes onwards, indicated with *. 771 
c. ADCP. Mice were injected with CD8+ depleting Ab (2.43). Before and after Ab injection, the 772 
number of CD8+ T cell in blood was determined by flow cytometry and depicted as percentage of 773 
CD8+/CD3+ cells of total lymphocyte population. Data shown are from one out of two experiments 774 
with similar results. Four FcγRI/II/III/IV-/- and two WT mice per group.  775 
Data was statistically analyzed with a T test at each time point, p=0.15 at day 0, and 0.0001 at day 776 
6 as compared to WT C57BL/6 mice. 777 
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 778 
Fig.3. FcγR involvement in the cross-presentation of IgG-IC derived Ag 779 
a. Uptake of IgG-IC derived Alexa488 labeled Ag by bone-marrow derived dendritic cells (BM-780 
DC) from WT and FcγRI/II/III/IV-/- mice measured by flow cytometry, presented as mean plus SD 781 
of three samples.  Extracellular binding was quenched by the addition of trypan blue. Depicted is 782 
percentage of Alexa488 positive cells out of total cell count. One representative experiment of two 783 
experiments performed is shown, statistical analysis was performed with T test. Asterisks indicate 784 
significant differences (***p<0.001) as compared to WT C57BL/6.  785 
b. BM-DC from FcγRI/II/III/IV-/- and WT C57BL/6 mice were incubated with OVA-IgG IC and 786 
subsequently co-cultured with T cell hybridoma B3Z which recognized an OVA-CTL epitope in 787 
MHC class I. Recognition leads to activation of the LacZ reporter gene which was measured with 788 
a β-galactosidase assay, and analyzed as absorption of light at OD590 nm. Minimal SIINFEKL 789 
OVA epitope was included as an MHC class I loaded positive control in both DC types. Presented 790 
as mean plus SEM, 4 samples per group. Statistical analysis was performed with a T test, 791 
(***p<0.001 for the mice that received immune complexes as compared to WT C57BL/6 mice   792 
c and d. WT C57BL/6 and FcγRI/II/III/IV-/- mice were injected with CFSE labeled OT-I T cells 793 
and subsequently injected with OVA with or without anti-OVA IgG. In vivo cross presentation 794 
was determined by analyzing the CFSE dilution of OT-I cells using flow-cytometry. Depicted are 795 
percentage of proliferating OT-I cells (CFSE fluorescence is diluted at least once) of total OT-I 796 
gated cells as mean of group plus SD (c) and representative CFSE plots (d). Data shown are from 797 
one out of two experiments with similar results. Five mice per group. Statistical analysis with T 798 
test per condition revealed no differences, p=0.63, 0.15, 0.73 respectively for OVA+Ab, OVA 799 
alone and naïve mice compared to WT C57BL/6 mice.   800 
e and f. Western blot analysis of the presence of Alexa488 labeled OVA in serum of mice at 801 
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different time-points after i.v. injection of the OVA anti-OVA IgG IC (e) and quantification of 802 
fluorescent OVA in Western Blot samples (f). Data shown are representative samples from three 803 
mice per experiment. Three experiments with similar results were performed.  804 
g. At different time-points after injection, mice were sacrificed and a single lobe of liver was 805 
isolated and imaged. Signal quantification of Alexa488 labeled IgG IC was performed. The 806 
fluorescent signal is shown as the total radiant efficiency (TRE), expressed in 807 
(photons/second)/(µW/cm²). The TRE/g liver in the time is shown. Data shown are from one out 808 
of two experiments with similar results. Three mice per group. 809 
 810 
Fig.4. Adaptive immune system is normal in FcγRI/II/III/IV-/- mice 811 
a. Lymphoid organs were harvested from two months old FcγRI/II/III/IV-/- and WT mice. Single 812 
cell suspensions were labeled with fluorescent Abs and analyzed using flow-cytometry. Each 813 
symbol represents an individual mouse. Data shown are from one out of two experiments with 814 
similar results. b. Mice were immunized three times with TNP-BSA. Serum samples were taken 8 815 
days after first boost and 7 and 12 days after second boost. Titres of anti-BSA antibodies were 816 
determined with ELISA. Data of day 12 are shown.  Other time points showed similar results. 817 
Eight mice per group, shown is mean plus SEM.  818 
 819 
Fig.5. T and B cell responses to Salmonella infection were similar in FcγRI/II/III/IV-/- and 820 
WT control mice.  821 
a. CD4+ T cells were positively enriched from splenocytes of groups of seven WT C57BL/6 and 822 
seven FcγRI/II/III/IV-/- mice infected 10 weeks earlier with STm SL3261. Groups of four WT 823 
C57BL/6 and four FcγRI/II/III/IV-/- naïve mice were also included in the experiment. The cells 824 
from individual mice were exposed to Salmonella Ag (salm) or anti-CD3 and anti-CD28 (pos) as a 825 
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positive control, or medium (neg), as negative control. IFNγ (left panel) and IL2 (right panel) were 826 
measured in the supernatants by ELISA after 72 and 24 hours respectively.  Data of one 827 
representative experiment out of two performed are shown. Statistical analysis using ANOVA did 828 
not show significant differences between WT C67BL/6 and FcγRI/II/III/IV-/-mice.  829 
b. Anti-STm LPS Abs were measured by ELISA in the sera of groups of five WT C57BL/6 and 830 
five FcγRI/II/III/IV-/- mice infected as in fig 5a. Groups of four naïve mice were included as 831 
controls. Ab titers are expressed as the reciprocal of the dilutions giving a reading equal to half of 832 
the maximal absorbance.  Data of one representative experiment out of two performed are shown.  833 
Statistical analysis was performed with T-test. Asterisks indicate significant difference. (* p< 834 
0.05) as compared to WT C57BL/6.  835 
 836 
Fig.6. IgG titres in older FcγRI/II/III/IV-/- and WT control mice 837 
a. IgG1, IgG2a and IgG2b titres were determined in sera of FcγRI/II/III/IV-/- and WT C57BL/6 838 
mice with ELISA, three mice per group. One representative experiment out of two performed is 839 
shown.  840 
b, c and d. IgG anti-dsDNA Ab titers (b) IgG anti-Chromatin titers (c) and IgG anti Histone titers 841 
(d), were determined by ELISA using anti-mouse γ chain-specific secondary Abs. Each symbol 842 
represents a mouse. Mean and SEM are shown with respective p-values. 843 
 844 
Fig.7. No differences in myeloid cell compartments between FcγRI/II/III/IV-/- and WT 845 
C57BL/6 control mice. 846 
a. Spleens of three months old FcγRI/II/III/IV-/- and WT C57BL/6 mice were incubated with 847 
Liberase, and single cell suspensions were labeled and analyzed by flow-cytometry. Graphs show 848 
the percentage CD8 positive or negative cells of CD11c+/CD19-/ B220-/7-AAD- cells. Three mice 849 
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per group. Data shown are from one out of two experiments with similar results. 850 
b. Spleens of three months old FcγRI/II/III/IV-/- and WT C57BL/6 mice were incubated with 851 
Liberase, and single cell suspensions were labeled and analyzed by flow-cytometry. Gating 852 
strategy was according to Shawn Rose et al (40), in short, gated on 7-aad-/CD19-/CD3- and 853 
followed by CD11c+ for CD11c+ group, CD11b+ for CD11b+ group, F4-80 +/-/ Ly6G+ for 854 
neutrophils, F4-80+/ Ly6G-/Ly6C+/-, SSC high for eosinophils, F4-80+/ Ly6G-/Ly6C+, SSC low 855 
monocyte/macrophage type I, F4-80+ /Ly6G-/Ly6C-, SSC low for monocyte/macrophage type II. 856 
Four mice per group. Data shown are from one out of two experiments with similar results. 857 
Statistical analysis performed with Sidak’s multiple comparisons test, showed that all groups were 858 
not significantly different from each other.  859 
   860 
Fig. 8. No differences in plasma concentrations and activity of complement factors between 861 
FcγRI/II/III/IV-/- mice and WT C57BL/6 control mice.  862 
a. Functional complement activity in plasma of WT C57BL/6 and FcγRI/II/III/IV-/- mice was 863 
determined for all three pathways (classical (CP), alternative (AP) and lectin pathway (LP), both 864 
at the level of C3 deposition and at the level of C9 deposition. Samples were tested in serial 865 
dilutions, quantified in comparison with a standard CD1 serum and depicted as AU/ml. Five mice 866 
per group. Statistical analysis with Sidak’s multiple comparison’s test revealed no significant 867 
difference between FcγRI/II/III/IV-/-.and WT C57/BL/6 mice.  868 
b. Individual complement factors were quantified in plasma of five mice per genotype using 869 
specific ELISAs. This includes C1q as inducer of the classical pathway, properdin as stabilizer of 870 
the alternative pathway, the central component C3 and C6 and C9 as part of the terminal pathway. 871 
Data are shown as the amounts per ml serum of the indicated factors either in μg (properdin, C6 872 
and C9) or in (AU) arbitrary units (C1q and C3 fragment). 873 
